Page 11 - Harvard Bioscience News Today

Cytek Biosciences (NASDAQ:CTKB – Get Rating) and Harvard Bioscience (NASDAQ:HBIO – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations. Analyst Recommendations This is a summary of current recommendations […]

/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Wall Street brokerages predict that Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) will announce $29.10 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Harvard Bioscience’s earnings, with the lowest sales estimate coming in at $29.00 million and the highest estimate coming in at $29.20 million. […]

Read our preview of key economic and company events in the week ahead, including interest rate decisions from the US Federal Reserve, Bank of England and the Reserve Bank of Australia, plus company updates from BP, Shell, AMC and more.

Equities analysts forecast that Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) will post sales of $29.10 million for the current quarter, according to Zacks. Two analysts have provided estimates for Harvard Bioscience’s earnings, with the lowest sales estimate coming in at $29.00 million and the highest estimate coming in at $29.20 million. Harvard Bioscience reported […]

StockNews.com initiated coverage on shares of Harvard Bioscience (NASDAQ:HBIO – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the medical instruments supplier’s stock. Separately, Zacks Investment Research downgraded shares of Harvard Bioscience from a hold rating to a sell rating in a research note on […]

Equities analysts expect Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) to report sales of $29.10 million for the current quarter, Zacks reports. Two analysts have issued estimates for Harvard Bioscience’s earnings, with the highest sales estimate coming in at $29.20 million and the lowest estimate coming in at $29.00 million. Harvard Bioscience reported sales of […]

Apple began introducing Force Touch (aka 3D Touch) to its devices in 2014 with the Apple Watch. It subsequently brought it to the MacBook's trackpad and the...